Amended Proxy Sets Reverse Split Range of 1-for-5 to 1-for-20

summarizeSummary

VivoSim Labs' amended proxy sets the reverse stock split ratio range at 1-for-5 to 1-for-20, giving the board discretion to choose the exact ratio. The filing also seeks approval for warrant-related share issuances and a warrant repricing.

check_boxKey Events · Corporate Governance and Compliance · VIVS

• Reverse Split Ratio Range Set

  The amended proxy specifies a reverse stock split ratio range of 1-for-5 to 1-for-20, with the board authorized to choose any ratio within that range at any time before September 30, 2027.

• Warrant Share Issuance Approval Sought

  Proposal 6 seeks approval for the issuance of 4,705,883 shares upon exercise of common warrants and a reduction of the exercise price of investor warrants from $9.60 to $0.85 per share.

• Potential Dilution from Warrants

  If the common warrants and investor warrants are fully exercised, existing stockholders would experience dilution of approximately 23.85% based on the current outstanding share count.

• Annual Meeting Scheduled

  The annual meeting is set for September 30, 2026, with a record date of August 13, 2026.

auto_awesomeAnalysis · VIVS · Life Sciences

The amended proxy specifies a reverse stock split ratio range of 1-for-5 to 1-for-20, giving the board discretion to choose any ratio within that range. This is a material detail for shareholders because it determines the post-split share count and price. At the current $0.33 price, a 1-for-20 split would raise the nominal price to $6.60, while a 1-for-5 split would result in $1.65. The company is seeking this to regain Nasdaq compliance and attract institutional investors, but the split itself does not change market capitalization. The filing also includes proposals to approve warrant share issuance and a warrant repricing, which together could significantly dilute existing holders.